Can ZEISS turn ophthalmology workflow software into the next battleground in cataract care?
ZEISS unveiled new AI, cataract planning, and cloud workflow tools at ASCRS 2026. Read what this means for ophthalmology practices.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Is Glaukos building a multi-franchise ophthalmology platform through Epioxa and glaucoma implants?
Glaukos heads to ASCRS 2026 with Epioxa and glaucoma data. Read what this could change for keratoconus, sustained therapy, and adoption.
Medical Devices & Diagnostics
Why Bausch + Lomb’s ASCRS 2026 data slate matters for premium IOL competition and dry eye care
Find out why Bausch + Lomb’s ASCRS 2026 data package could reshape competition in cataract surgery, dry eye care, and ophthalmology platforms.
Pharma & Biotech
What Affinia Therapeutics’ UPBEAT trial reveals about the next phase of inherited heart failure gene therapy
Affinia Therapeutics has cleared AFTX-201 for a Canadian BAG3 DCM trial. Read why the gene therapy’s design and risks matter now.
Pharma & Biotech
How Florida Cancer Specialists contributed to a study that may change KRAS G12D cancer treatment
Setidegrasib showed early activity in KRAS G12D lung and pancreatic cancers. Read why the Phase 1 signal could matter for oncology’s next target.
Pharma & Biotech
Why Vyome’s VT-1953 data could reshape supportive oncology care in advanced cancer wounds
Vyome’s VT-1953 heads to AACR 2026 with Phase 2 data in malignant fungating wounds. Read what this could change for supportive oncology.
Pharma & Biotech
Can ZIVO Bioscience finally scale Zivolife after securing Cyanotech as its manufacturing partner?
ZIVO Bioscience’s Cyanotech deal could reshape the Zivolife commercialization story. Read why manufacturing may now matter more than hype.
Medical Devices & Diagnostics
Is Alcon redefining the enhanced monofocal category with Clareon TruPlus at ASCRS 2026?
Alcon launched Clareon TruPlus at ASCRS 2026. Read why the new enhanced monofocal IOL could reshape cataract lens choice.
Pharma & Biotech
Why ABION’s ABN202 may be aiming beyond TROP2 antibody-drug conjugate resistance
ABION’s ABN202 showed preclinical promise against TROP2 ADC resistance at AACR 2026. Read what this could mean for solid tumor oncology.
Pharma & Biotech
What the Nexus Pharmaceuticals cyclophosphamide launch reveals about competition in sterile generic oncology drugs
Nexus Pharmaceuticals has launched cyclophosphamide injection in ready-to-dilute vials. Read what this means for oncology workflows and generic drug access.